Ditchcarbon
  • Contact
  1. Organizations
  2. Sangui Biotech International, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
DE
updated a month ago

Sangui Biotech International, Inc. Sustainability Profile

Company website

Sangui Biotech International, Inc., often referred to as Sangui Biotech, is a pioneering company headquartered in Delaware, USA. Founded in 2001, the firm operates primarily in the biotechnology sector, focusing on innovative solutions for medical and therapeutic applications. With a commitment to advancing healthcare, Sangui Biotech has developed a range of unique products, including cutting-edge blood substitutes and advanced wound care technologies. The company has achieved significant milestones, positioning itself as a leader in the field of biopharmaceuticals. Its core offerings are distinguished by their ability to enhance patient outcomes and improve quality of life. With a strong presence in both domestic and international markets, Sangui Biotech continues to drive innovation and maintain a competitive edge in the rapidly evolving biotechnology landscape.

DitchCarbon Score

How does Sangui Biotech International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Sangui Biotech International, Inc.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.

17%

Let us know if this data was useful to you

Sangui Biotech International, Inc.'s reported carbon emissions

Sangui Biotech International, Inc., headquartered in Delaware, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Sangui Biotech may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the industry increasingly prioritises climate action, it will be essential for Sangui Biotech to consider developing and communicating its environmental strategies to align with global climate goals.

How Carbon Intensive is Sangui Biotech International, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sangui Biotech International, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Sangui Biotech International, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sangui Biotech International, Inc. is in DE, which has a medium grid carbon intensity relative to other regions.

Sangui Biotech International, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Sangui Biotech International, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Sangui Biotech International, Inc.'s Emissions with Industry Peers

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 20 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 9 minutes ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated less than a minute ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251210.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy